Citadel Advisors
NRXP icon

Citadel Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Citadel Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Buy
+26,700
New +$88.2K ﹤0.01% 12627
2025
Q1 		– Sell
-2,600
Closed -$5.72K – 15251
2024
Q4 		$5.72K Buy
2,600
+1,600
+160% +$2.15K ﹤0.01% 13843
2024
Q3 		$1.69K Buy
1,000
+150
+18% +$302 ﹤0.01% 13821
2024
Q2 		$2.07K Sell
850
-110
-11% -$391 ﹤0.01% 13738
2024
Q1 		$4.53K Buy
960
+870
+967% +$4.01K ﹤0.01% 13806
2023
Q4 		$414 Sell
90
-340
-79% -$1.12K ﹤0.01% 14034
2023
Q3 		$1.12K Sell
430
-20
-4% -$67 ﹤0.01% 13916
2023
Q2 		$2.18K Sell
450
-660
-59% -$3.97K ﹤0.01% 13815
2023
Q1 		$7.32K Buy
1,110
+260
+31% +$2.63K ﹤0.01% 13736
2022
Q4 		$9.44K Sell
850
-1,600
-65% -$16.1K ﹤0.01% 13683
2022
Q3 		$18K Sell
2,450
-760
-24% -$5.12K ﹤0.01% 12110
2022
Q2 		$19K Sell
3,210
-4,290
-57% -$56.4K ﹤0.01% 12425
2022
Q1 		$184K Sell
7,500
-12,130
-62% -$395K ﹤0.01% 11636
2021
Q4 		$938K Sell
19,630
-17,770
-48% -$1.28M ﹤0.01% 8122
2021
Q3 		$3.47M Buy
+37,400
New +$4.87M ﹤0.01% 5051

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors's NRXP Position: Q2 2026 in Review

Citadel Advisors opened a new position in NRX Pharmaceuticals (NRXP) in Q2 2026: 680,043 shares worth $2.78M. The stake represents ﹤0.01% of the portfolio and ranks #5832 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in NRXP as recently as Q2 2025.

Citadel Advisors first reported a position in NRXP in Q3 2021 and has held it in 7 quarters since. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Citadel Advisors held 680,043 shares of NRX Pharmaceuticals worth $2.78M as of Q2 2026.
  • NRX Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5832 holding.
  • Citadel Advisors first reported a position in NRX Pharmaceuticals in Q3 2021 and has held it in 7 quarters since.
  • 47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.